一、持续督导工作情况 根据《证券发行上市保荐业务管理办法》、《上海证券交易所科创板股票上市 规则》、《上海证券交易所上市公司自律监管指引第 11 号——持续督导》等有关 法律、法规的规定，东方证券承销保荐有限公司（以下简称"保荐机构"）作为 上海三友医疗器械股份有限公司（以下简称"三友医疗"、"公司"）持续督导工 作的保荐机构，负责三友医疗上市后的持续督导工作，并出具本持续督导跟踪报 告。 | 序 | 工作内容 | 持续督导情况 | | --- | --- | --- | | 号 | | 保荐机构已建立健全并有效执行了持 | | 1 | 建立健全并有效执行持续督导工作制度，并针对具体的 | 续督导制度，并制定了相应的工作计 | | | 持续督导工作制定相应的工作计划 | 划 | | | 根据中国证监会相关规定，在持续督导工作开始前，与 | 保荐机构已与三友医疗签订承销与保 | | 2 | 上市公司或相关当事人签署持续督导协议，明确双方在 | 荐协议，该协议明确了双方在持续督 | | | 持续督导期间的权利义务，并报上海证券交易所备案 | 导期间的权利和义务，并报上海证券 | | | | 交易所备案 | | | ...

（二）审议通过《关于使用部分闲置募集资金暂时补充流动资金的议案》 证券代码：688085 证券简称：三友医疗 公告编号：2023-030 上海三友医疗器械股份有限公司 第三届监事会第五次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）第三 届监事会第五次会议于 2023 年 8 月 24 日在公司会议室以现场方式召开。本次会 议的通知于 2023 年 8 月 14 日通过邮件等方式送达全体监事。会议应出席监事 3 人，实际到会监事 3 人，会议由监事会主席马宇立先生主持，本次监事会会议的 召集和召开程序符合有关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定，会议决议合法、有效。 二、监事会会议审议情况 （一）审议通过《关于公司<2023 年半年度报告及摘要>的议案》 议案内容：详见公司同日刊载于上海证券交易所网站（www.sse.com.cn）的 公司《2023 年半年度报告》及《2023 年半年度报告摘要》。 ...

证券代码：688085 证券简称：三友医疗 公告编号：2023-031 上海三友医疗器械股份有限公司 关于参加2023 半年度医疗器械及医疗设备行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2023 年 9 月 5 日(星期二) 下午 13:00-15:00 会议召开方式：上证路演中心网络文字互动 会议召开地点：上海证券交易所上证路演中心（http://roadshow.sseinfo.co m/） 投资者可于 2023 年 9 月 4 日(星期一)16:00 前通过电话或公司邮箱 ir@sanyou-medical.com 进行提问。公司将在文字互动环节对投资者普遍关注的问题 进行回答。 上海三友医疗器械股份有限公司（以下简称"公司"）已于 2023 年 8 月 25 日 发布公司 2023 半年度报告，为便于广大投资者更全面深入地了解公司 2023 半年度 经营成果、财务状况、发展理念，公司参与了由上交所主办的 2023 半年度医疗器 械及医疗设备行业集体业绩 ...

上海三友医疗器械股份有限公司独立董事 关于公司第三届董事会第七次相关议案的独立意见 上海三友医疗器械股份有限公司(以下简称"公司")于 2023年 8 月 24 日召开 了第三届董事会第七次会议。我们作为公司的独立董事,在仔细审阅和分析了第三 届董事会第七次会议的相关文件后,发表如下独立意见: 一、《关于使用部分闲置募集资金暂时补充流动资金的议案》 我们认为,公司本次使用部分闲置募集资金暂时补充流动资金与募集资金投资 项目的实施计划不抵触,不影响募集资金投资项目的正常进行,不存在变相改变募 集资金投向的情形,不存在损害公司及股东特别是中小股东利益的情形,符合公司 生产经营需求,有利于提高公司的资金使用效率和降低财务费用。公司本次使用部 分暂时闲置募集资金暂时补充流动资金,符合《上市公司监管指引第 2 号--上市公 司募集资金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监管指 引第1号--规范运作》等有关规定,内容及程序合法合规。 我们一致同意公司本次使用部分闲置募集资金暂时补充流动资金事项。 二、《关于<公司 2023 年半年度募集资金存放与使用情况的专项报告>的议案》 我们认为,公司2023年半 ...

使用部分闲置募集资金暂时补充流动资金的 核查意见 东方证券承销保荐有限公司（以下简称"东方投行"或"保荐机构"）作为上海 三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）首次公开发行股票 并在科创板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证 券交易所科创板股票上市规则》《上市公司监管指引第 2 号——上市公司募集资 金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》《上海证券交易所上市公司自律监管指引第 11 号——持续督 导》等法律法规的相关规定，对三友医疗本次拟使用部分闲置募集资金暂时补充 流动资金事项进行了专项核查，具体核查情况如下： 东方证券承销保荐有限公司 关于上海三友医疗器械股份有限公司 一、募集资金基本情况 三、本次使用闲置募集资金暂时补充流动资金情况 在保证募集资金投资项目建设的资金需求和募集资金投资项目正常进行的 前提下，为满足公司流动资金需求，提高募集资金的使用效率，降低财务成本， 进一步提高公司盈利能力，维护上市公司和股东利益，根据《上市公司监管指引 第 2 号——上市公司募集资金管理和使用的监管要求》和公司《募集资金管 ...

经上海证券交易所科创板上市委员会 2020 年 1 月 8 日审核同意，并经中国 证券监督管理委员会于 2020 年 3 月 12 日《关于同意上海三友医疗器械股份有限 公司首次公开发行股票注册的批复》（证监许可〔2020〕402 号），公司获准向 社会公开发行人民币普通股 51,333,500 股，每股面值人民币 1.00 元，每股发行 价为人民币 20.96 元，合计募集资金人民币 1,075,950,160.00 元，扣除各项发 行费用（不含税）人民币 97,892,778.72 元后，募集资金净额为 978,057,381.28 元。上述募集资金已全部到位，并由立信会计师事务所（特殊普通合伙）验证并 出具"信会师报字[2020]第 ZA10508 号"验资报告。 根据有关法律、法规及《上海证券交易所上市公司募集资金管理办法（2013 年修订）》的要求，公司已对募集资金进行专户存储，并与保荐机构东方证券承 销保荐有限公司（原名"东方花旗证券有限公司"，以下简称"东方投行"）、 存放募集资金的银行签署了《募集资金专户存储三方监管协议》。具体情况详见 1 证券代码：688085 证券简称：三友医疗 公告编号 ...

上海三友医疗器械股份有限公司（以下简称"三友医疗"或"公司"）于 2022 年 8 月 19 日召开第三届董事会第二次会议、第三届监事会第二次会议，审议通 过了《关于使用部分闲置募集资金暂时补充流动资金的议案》，同意公司使用不 超过 8,000.00 万元（含本数）闲置募集资金暂时补充流动资金，用于与公司主 营业务相关的生产经营使用，使用期限自公司董事会审议通过之日起不超过 12 个月。具体内容请详见公司于 2022 年 8 月 23 日在上海证券交易所网站 （www.sse.com.cn）及指定信息披露媒体披露的《上海三友医疗器械股份有限公 司关于使用部分闲置募集资金暂时补充流动资金的公告》（公告编号：2022-028）。 根据上述决议，公司在规定期限内实际使用人民币 75,025,023.40 元闲置募 集资金暂时补充流动资金，并对资金进行了合理的安排与使用，未影响募集资金 投资计划的正常进行，资金运用情况良好。 2023 年 8 月 17 日，公司将上述暂时补充流动资金的人民币 75,025,023.40 元全部归还至募集资金专用账户。上述募集资金的归还情况已通知公司的保荐机 构及保荐代表人。 证券代码 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 160.84 million, representing a year-on-year increase of 24.19%[6] - The net profit attributable to shareholders for the same period was CNY 34.65 million, an increase of 4.48% compared to the previous year[6] - The gross profit margin for the period was 85.48%, a decrease of 5.25 percentage points year-on-year due to increased depreciation and amortization from new facilities and equipment[16] - Total revenue for Q1 2023 reached ¥160,838,817.82, an increase from ¥129,507,582.55 in Q1 2022, representing a growth of approximately 24.2%[23] - Net profit for Q1 2023 was ¥35,107,002.53, compared to ¥32,719,296.35 in Q1 2022, reflecting an increase of approximately 7.3%[24] - The net profit attributable to the parent company for Q1 2023 was ¥34,653,466.77, compared to ¥33,167,361.09 in Q1 2022, reflecting an increase of approximately 4.48%[25] Cash Flow - The net cash flow from operating activities surged by 129.49% to CNY 40.03 million, attributed to improved management of accounts receivable[11] - The net cash flow from operating activities for Q1 2023 was ¥40,031,108.96, significantly up from ¥17,443,719.86 in Q1 2022, indicating a growth of about 129.61%[28] - The total cash inflow from operating activities was CNY 156,833,271.94 in Q1 2023, compared to CNY 139,749,754.40 in Q1 2022, showing an increase of 12.2%[37] - The cash flow from financing activities showed a net outflow of ¥542,245.57 in Q1 2023, compared to a net outflow of ¥870,801.91 in Q1 2022, indicating a reduction in cash outflow by approximately 37.77%[29] Assets and Liabilities - Total assets at the end of Q1 2023 reached CNY 2,226.59 million, reflecting a 1.61% increase from the end of the previous year[7] - Total assets as of Q1 2023 were ¥2,226,594,090.66, an increase from ¥2,191,365,967.39 at the end of Q1 2022[22] - The total liabilities as of Q1 2023 amounted to CNY 245,765,691.29, up from CNY 232,256,680.92 in the previous year, reflecting a growth of 5.0%[33] Equity and Shareholder Information - The total equity attributable to shareholders increased to CNY 1,874.42 million, up 1.88% from the end of the previous year[7] - The company's equity increased to ¥1,948,145,447.35 in Q1 2023 from ¥1,913,016,196.72 in Q1 2022, showing a growth of approximately 1.8%[22] - The company had a total of 7,458 common shareholders at the end of the reporting period[12] Research and Development - The company's R&D investment totaled CNY 14.27 million, accounting for 8.87% of operating revenue, a decrease of 0.63 percentage points year-on-year[6] - The company's research and development expenses for Q1 2023 were CNY 6,039,616.74, down 27.5% from CNY 8,344,516.34 in Q1 2022[35] - Research and development expenses for Q1 2023 amounted to ¥14,269,124.81, compared to ¥12,307,973.63 in Q1 2022, marking a growth of around 15.9%[24] Investments and Expansion - The company completed the construction and commissioning of a new 40,000 square meter facility in Suzhou Taicang to meet the increased demand following the implementation of spinal collection procurement[16] - The company made a second investment payment of EUR 2.5 million to Implanet, increasing its ownership stake to 43.14%, making it the largest single shareholder[17] - The approval of the 5mm ultrasonic hemostatic knife by the National Medical Products Administration enhances the product's capabilities and expands its application in more complex surgeries[17] Market Strategy - The company is focusing on market access and sales channel expansion in response to the competitive environment created by the procurement policy[16] - The company anticipates further growth in surgical volumes as it adapts to the new procurement landscape[16]

Financial Performance - The company's operating revenue for 2022 was RMB 649.15 million, representing a 9.40% increase compared to RMB 593.36 million in 2021 [27]. - The net profit attributable to shareholders for 2022 was RMB 190.82 million, a 2.39% increase from RMB 186.37 million in 2021 [27]. - The net profit after deducting non-recurring gains and losses was RMB 133.82 million, up 6.47% from RMB 125.69 million in 2021 [27]. - The net cash flow from operating activities was RMB 155.97 million, reflecting a 7.63% increase from RMB 144.92 million in 2021 [27]. - The total assets at the end of 2022 were RMB 2,191.37 million, a 9.72% increase from RMB 1,997.17 million at the end of 2021 [27]. - The net assets attributable to shareholders at the end of 2022 were RMB 1,839.74 million, a 9.13% increase from RMB 1,685.85 million at the end of 2021 [27]. - The basic earnings per share for 2022 were RMB 0.84, a slight increase of 1.20% from RMB 0.83 in 2021 [28]. - The company reported a total R&D investment of 60.38 million yuan in 2022, an increase of 6.76% from the previous year, accounting for 9.30% of total revenue [116]. Dividend and Capital Changes - The company plans to distribute a cash dividend of 0.85 CNY per 10 shares, totaling approximately 19.2 million CNY, which represents 10.06% of the net profit attributable to shareholders [7]. - The total share capital will increase from 225,866,850 shares to 248,453,535 shares due to a capital reserve conversion plan, distributing 1 additional share for every 10 shares held [7]. - The profit distribution and capital reserve conversion plan are subject to approval at the upcoming annual general meeting [8]. Audit and Compliance - The company received a standard unqualified audit report from Dahua Certified Public Accountants [6]. - The board of directors and management have confirmed the accuracy and completeness of the financial report [7]. - There are no non-operating fund occupations by controlling shareholders or related parties [11]. - The company has not violated any decision-making procedures regarding external guarantees [11]. - The company has established a comprehensive governance structure to ensure compliance and effective decision-making, enhancing transparency and investor relations [52]. Market and Product Development - The company plans to continue expanding its market presence and investing in new technologies and products [30]. - The company achieved significant improvements in production efficiency through lean production initiatives, enhancing delivery rates and reducing production deviations [50]. - The company is focusing on R&D in orthopedic fields, including spinal implants and ultrasound-powered devices, while also exploring new technologies like smart surgical robots and biomaterials [54]. - The company is expanding its international market presence, particularly in Europe, the United States, and Australia, to strengthen its competitive position [54]. - The company has established partnerships with multiple top-tier hospitals to enhance clinical research and innovation in orthopedic treatments [128]. Product Innovations - The company has successfully launched innovative products in the spinal implant sector, improving treatment outcomes and gaining recognition from medical professionals [55]. - The company’s new spinal high-end nail and rod orthopedic system is expected to launch globally in 2023 [37]. - The third-generation Duetto dual-head screw product was officially launched, enhancing operational capabilities in complex deformity correction surgeries [38]. - The new spinal posterior fixation system received regulatory approval, improving the company's competitive edge in the spinal orthopedic market [39]. - The company has developed advanced core technologies in orthopedic implant consumables, including multi-plane adjustment and bone-matching pedicle screw technology, which are patented and industry-leading [102]. Risks and Challenges - The company has outlined potential risks in its operations, which investors are advised to review in the management discussion and analysis section [5]. - The company is facing risks related to new product development failures and market acceptance, which could impact expected economic benefits [141]. - The company has a risk of core technology leakage, which could adversely affect its operations if competitors infringe on patents or if internal leaks occur [142]. - The company is facing risks from potential disruptions due to recurring COVID-19 outbreaks affecting domestic and international operations [154]. Strategic Investments - The company invested €5 million in Implanet, becoming its largest single shareholder, to enhance international business development and market presence [47]. - The company acquired 51% of Yunhejing from Dakong Holdings in January 2022, and established Sanyou (Hong Kong) in September 2022, along with Shanghai Xianlv in November 2022, expanding its consolidation scope [165][180]. - The company plans to use raised funds for orthopedic implant expansion, product R&D center construction, and marketing network development, with ongoing projects facing potential delays due to external factors [148]. Regulatory Environment - The regulatory environment for medical devices in China is stringent, requiring multiple certifications and quality management systems for production [88]. - The company has achieved CE certification and FDA registration for most products, laying a solid foundation for expanding into domestic and international markets [135].

证券代码：688085 证券简称：三友医疗 公告编号：2023-019 重要内容提示： （网址：http://roadshow.sseinfo.com/） 上海三友医疗器械股份有限公司 关于参加上海辖区上市公司 2022 年报集体业绩说明会暨 2023 年第一季度暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 投资者可于 2023 年 4 月 26 日(星期三)至 5 月 9 日(星期二)16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@sanyou-medical.com 进行提问。公司将在说明会上对投资者普遍关注 的问题进行回答。 为进一步加强与广大投资者的沟通交流，上海三友医疗器械股份有限公 司（以下简称"公司"）将参加"2023 年上海辖区上市公司年报集体业绩说 明会"活动，现将有关事项公告如下： 1 会议召开时间：2023 年 05 月 10 日(星期三)下午 15:00-17:00 会议召开式：上证路演中心网络互动 会议召开方地点：上海证券交易所上证路演 ...